TSHA
Taysha Gene Therapies, Inc.Price
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 4 ▼ 1 insider sell $7.5K at $4.52
- Apr 10 ▼ 1 insider sell $892.0K at $4.46
- Apr 27 ▲ Taysha Gene Therapies announced positive preclinical in vitro data f…
- May 6 Taysha reported Q1 2026 EPS of -$0.12 (GAAP), wider than the -$0.08…
- Jun 5 Activist stake: Taysha Gene Therapies Announces Inducement Grant Under Nas…
- Jun 24 Activist stake: Taysha Gene Therapies Announces Proposed Public Offering o…
- Jun 25 ▼ Taysha Gene Therapies is raising approximately $187.4 million ($215.…
- Jun 25 ▼ Taysha Gene Therapies announced the pricing of a $200M underwritten…
- Jun 25 Offering: Taysha Gene Therapies Announces Pricing of Public Offering…
- Jul 10 ▼ 1 insider sell $1.2M at $6.24
- Aug 3 Contract: Taysha Gene Therapies and Catalent Expand Strategic Partne…
- Sep 17 Wolfe Research initiates
Signal stack
Where each data set points today.
- InsidersBEARISH
2 insiders sold $2.1M.
- InstitutionsBULLISH
Q3 2026: 27 added (1 new), 11 trimmed or exited. Largest new: Capitolis Liquid Global Markets $11.2M.
- AnalystsBULLISH
18 of 19 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest +4.3% to 53.48M shares. 14.8 days to cover, ≈16.4% of shares.
- TrendRANGE
9% below its 50-day average.
- SocialQUIET
No Reddit mentions this week. Last mention Nov 5.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Aberdeen Group plc | ADD | $18.3M |
| CAPITOLIS LIQUID GLOBAL MARKETS LLC | NEW | $11.2M |
| FIRST TRUST ADVISORS LP | ADD | $5.7M |
| Qube Research & Technologies Ltd | DOUBLED | $4.4M |
| Nuveen, LLC | ADD | $3.4M |
| DIMENSIONAL FUND ADVISORS LP | ADD | $3.3M |
| VICTORY CAPITAL MANAGEMENT INC | DOUBLED | $2.6M |
| ALPS ADVISORS INC | ADD | $2.1M |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
19 analystsPrice is below the lowest target. Median implies +196%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Sep 17, 2026 | Wolfe Research INITIATE | Outperform |
| Jul 21, 2026 | Goldman Sachs MAINTAIN | Buy |
| Jul 2, 2026 | Citizens REITERATE | Market Outperform |
| Jun 30, 2026 | Needham MAINTAIN | Buy |
| Jun 30, 2026 | Baird MAINTAIN | Outperform |
| Jun 23, 2026 | BMO Capital MAINTAIN | Outperform |
Washington
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
Nagendran Sukumar President and Head of R&D Jul 10, 2026 | SELL | $1.2M |
Long Alison S Director Jun 1, 2026 | AWARD | 21,335 sh |
Stalfort John A III Director Jun 1, 2026 | AWARD | 21,335 sh |
Long Alison S Director Jun 1, 2026 | AWARD | 42,671 sh |
Donenberg Phillip B. Director Jun 1, 2026 | AWARD | 21,335 sh |
Donenberg Phillip B. Director Jun 1, 2026 | AWARD | 42,671 sh |
Sepp-Lorenzino Laura Director Jun 1, 2026 | AWARD | 42,671 sh |
Stalfort John A III Director Jun 1, 2026 | AWARD | 42,671 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | 🔒 Fresh data, subscribers only | |||
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | 🔒 Fresh data, subscribers only | |||
Short side
FINRA· Oct 30, 2026SecBot reports
9 filings · 4 press releases · 0 bullish · 1 bearish · 2 mixed · 6 neutral- NEUTRAL PRESS-RELEASENov 12, 2026
Taysha Gene Therapies reported a Q3 2026 net loss of $0.10 per share, narrower than the consensus…
The key binary catalyst is the 1H 2027 data readout and FDA feedback on the TSHA-102 BLA pathway. Monitor for any safety signals or efficacy trends from the 6-month interim analysis, as well as the…
- NEUTRAL PRESS-RELEASEAug 11, 2026
Taysha Gene Therapies reported Q2 2026 EPS of -$0.13, missing consensus of -$0.11 by 18.2%, with…
The earnings miss is secondary to the pipeline catalyst timeline. Monitor for REVEAL pivotal trial topline data and FDA feedback in 1H 2027, which will determine TSHA-102's BLA path. The $230M cash…
- MIXED 8-KJun 25, 2026
Taysha Gene Therapies priced a $200M underwritten public offering of 32,500,001 common shares at…
The substantial dilutive raise at a discount gives the company cash into H2 2028 but weighs on near-term valuation. Watch for the efficacy of TSHA-102 clinical data as the primary catalyst, cash…
- BEARISH 424B5Jun 25, 2026
Taysha Gene Therapies is raising approximately $187.4 million ($215.6 million if underwriters'…
Traders should monitor post-offering price action for TSHA given the 13.6% discount to prior close, anticipate near-term selling pressure as the market absorbs ~32.5M new shares. The 60-day lockup…
All TSHA filing & press-release reports (13)
- PRESS-RELEASE reportNov 12, 2026
- PRESS-RELEASE reportAug 11, 2026
- 424B5 reportJun 25, 2026
- 8-K reportJun 25, 2026
- PRESS-RELEASE reportJun 24, 2026
- PRESS-RELEASE reportJun 5, 2026
- 8-K reportMay 6, 2026
- PRESS-RELEASE reportMay 6, 2026
- PRESS-RELEASE reportApr 29, 2026
- PRESS-RELEASE reportApr 27, 2026
- DEFA14A reportApr 22, 2026
- 144 reportApr 10, 2026
- PRESS-RELEASE reportMar 19, 2026